Orphan drugs and haemophiliaWritten by Flora Peyvandi
Speaker: Prof Flora Peyvandi,
Head of the Department Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,
Fondazione IRCCS CĂ Granda, Ospedale Maggiore Policlinico, University of Milan, Italy.
Flora Peyvandi is Associate Professor of Internal Medicine and Head of the Department Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS CĂ Granda, Ospedale Maggiore Policlinico, University of Milan, Italy. She is responsible for the haematology outpatient clinic for haemophilia, rare bleeding disorders, haemorrhagic and thrombotic diseases, reproductive assistance to HIV discordant couples and prenatal diagnosis.
Dr Peyvandi received her medical degree from the University of Milan, Italy and is certified in Haematology. She holds a PhD in â€śRare bleeding disordersâ€ť from the University of Maastricht, The Netherlands. As part of her PhD thesis on the molecular characterisation and mechanisms of FVII and FX deficiencies she conducted research at various institutions: the Royal Free Hospital, University College, London, UK, the Veteran Administration Hospital, Harvard University, Boston, USA and the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center. Dr Peyvandiâ€™s research interests include the characterisation of coagulation factors involved in rare coagulation disorders and the ADAMTS-13 gene and protein in thrombotic thrombocytopenic purpura (TTP) patients. She further is involved in the implementation of an International Rare Bleeding Disorders Database (RBDD) and in the implementation of a TTP data base (www.ttpdatabase.org). Other focuses of her research are the development of new techniques for prenatal diagnosis in early stage of pregnancy in women carriers and the characterisation of molecular mechanisms of FVIII in haemophilic patients with inhibitors.